Rehavi M - Search Results

1

Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.

Zalsman G, Aslanov-Farbstein D, Rehavi M, Roz N, Vermeiren R, Laor N, Weizman A, Toren P. Zalsman G, et al. Among authors: rehavi m. J Child Adolesc Psychopharmacol. 2011 Aug;21(4):341-4. doi: 10.1089/cap.2010.0148. J Child Adolesc Psychopharmacol. 2011. PMID: 21851191

2

Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.

Rehavi M, Roz N, Weizman A. Rehavi M, et al. Eur Neuropsychopharmacol. 2002 Jun;12(3):261-8. doi: 10.1016/s0924-977x(02)00021-4. Eur Neuropsychopharmacol. 2002. PMID: 12007678

3

Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.

Toren P, Rehavi M, Luski A, Roz N, Laor N, Lask M, Weizman A. Toren P, et al. Among authors: rehavi m. Eur Neuropsychopharmacol. 2005 Mar;15(2):159-62. doi: 10.1016/j.euroneuro.2004.07.002. Eur Neuropsychopharmacol. 2005. PMID: 15695060

4

Decreased platelet vesicular monoamine transporter density in habitual smokers.

Schwartz K, Weizman A, Rehavi M. Schwartz K, et al. Among authors: rehavi m. Eur Neuropsychopharmacol. 2005 Mar;15(2):235-8. doi: 10.1016/j.euroneuro.2004.11.001. Eur Neuropsychopharmacol. 2005. PMID: 15695071

5

Reduced platelet vesicular monoamine transporter density in Tourette's syndrome pediatric male patients.

Ben-Dor DH, Zimmerman S, Sever J, Roz N, Apter A, Rehavi M, Weizman A. Ben-Dor DH, et al. Among authors: rehavi m. Eur Neuropsychopharmacol. 2007 Jul;17(8):523-6. doi: 10.1016/j.euroneuro.2007.01.002. Epub 2007 Mar 6. Eur Neuropsychopharmacol. 2007. PMID: 17344033

6

Altered affinity of the platelet vesicular monoamine transporter 2 to dihydrotetrabenazine in children with major depression.

Zalsman G, Rehavi M, Roz N, Laor N, Weizman A, Toren P. Zalsman G, et al. Among authors: rehavi m. J Neural Transm (Vienna). 2011 Sep;118(9):1383-7. doi: 10.1007/s00702-011-0643-4. Epub 2011 Apr 12. J Neural Transm (Vienna). 2011. PMID: 21484276 Clinical Trial.

7

Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.

Zucker M, Valevski A, Weizman A, Rehavi M. Zucker M, et al. Among authors: rehavi m. Eur Neuropsychopharmacol. 2002 Aug;12(4):343-7. doi: 10.1016/s0924-977x(02)00041-x. Eur Neuropsychopharmacol. 2002. PMID: 12126874

8

Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression.

Zucker M, Aviv A, Shelef A, Weizman A, Rehavi M. Zucker M, et al. Among authors: rehavi m. Psychiatry Res. 2002 Nov 15;112(3):251-6. doi: 10.1016/s0165-1781(02)00223-8. Psychiatry Res. 2002. PMID: 12450634

9

Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.

Schwartz K, Yadid G, Weizman A, Rehavi M. Schwartz K, et al. Among authors: rehavi m. Brain Res. 2003 Mar 7;965(1-2):174-9. doi: 10.1016/s0006-8993(02)04167-7. Brain Res. 2003. PMID: 12591135

10

Repeated swim stress leads to down-regulation of vesicular monoamine transporter 2 in rat brain nucleus accumbens and striatum.

Zucker M, Weizman A, Rehavi M. Zucker M, et al. Among authors: rehavi m. Eur Neuropsychopharmacol. 2005 Mar;15(2):199-201. doi: 10.1016/j.euroneuro.2004.08.009. Eur Neuropsychopharmacol. 2005. PMID: 15695065

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters